GSK (GSK) said Thursday that the US Food and Drug Administration has approved the use of monoclonal antibody mepolizumab, Nucala, as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease.
The approval follows "positive" results from the company's Matinee and Metrex phase III trials. During the trials, mepolizumab, when used with triple inhaled therapy, showed significant reduction in the annualized rate of moderate and severe exacerbations against placebo in COPD patients with an eosinophilic phenotype, the company said.
GSK said regulatory submissions for mepolizumab's use in COPD are currently under review in China and Europe. It has not been approved for use in COPD in any other country.
Price: 38.94, Change: +0.40, Percent Change: +1.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.